Abstracts tagged "Randomized Trial"

Abstract Number: 0593 • ACR Convergence 2024
Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Alvin F. Wells¹, Arthur Kavanaugh², William Tillett³, Philip S. Helliwell⁴, Marijn Vis⁵, Yuri Klyachkin⁶, Cynthia Deignan⁷, Lichen Teng⁷, Rebecca Wang⁷ and Alexis Ogdie⁸, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of California San Diego, La Jolla, CA, ³Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶Amgen, Lexington, KY, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) score is a composite of 3 patient-reported outcomes (PROs): Health Assessment Questionnaire (HAQ), pain visual…
Abstract Number: 1465 • ACR Convergence 2024
The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial
Laure Gossec¹, Laura Coates², Dafna Gladman³, Alexis Ogdie⁴, Peter Nash⁵, Denis Poddubnyy⁶, Arthur Kavanaugh⁷, April Armstrong⁸, Carlo Selmi⁹, Ruben Queiro Silva¹⁰, Cynthia Deignan¹¹, Rebecca Wang¹¹, Jyotsna Reddy¹¹, Michele Brunori¹¹ and Philip Mease¹², ¹Sorbonne Université, Paris, France, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, ⁶Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁷University of California, San Diego, School of Medicine, La Jolla, CA, ⁸University of California Los Angeles, Los Angeles, CA, ⁹Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ¹⁰Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Oligoarticular psoriatic arthritis (PsA, ≤4 joints affected) is common but understudied, as most clinical trials enroll patients (pts) with ≥3 swollen and tender joints.…
Abstract Number: 1676 • ACR Convergence 2024
Changing Patients’ Mindsets About Non-Severe Side Effects of Methotrexate: A Randomized Controlled Trial
Rachael Yielder¹, Kari Leibowitz², Alia Crum², Paul Manley³, Nicola Dalbeth¹ and Keith Petrie⁴, ¹University of Auckland, Auckland, New Zealand, ²Stanford University, Palo Alto, CA, ³Te Whatu Ora Health New Zealand, Auckland, New Zealand, ⁴The University of Auckland, Auckland, New Zealand
Background/Purpose: Although methotrexate (MTX) is a first-line treatment for inflammatory rheumatic diseases, side effects can lead to poor adherence and persistence. A novel intervention involves…
Abstract Number: 2185 • ACR Convergence 2024
TRACER: Transition to Adulthood Through Coaching and Empowerment in Rheumatology, a Feasibility Study
Megan Clarke¹, Julie Herrington², Tania Cellucci³, Liane Heale⁴, Mark Matsos⁵, KAREN BEATTIE², Roberta A Berard⁶ and Michelle Batthish³, ¹McMaster Universitys, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada, ⁴McMaster University, Oakville, ON, Canada, ⁵McMaster Lupus Clinic, Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada, ⁶London Health Sciences Centre, London, ON, Canada
Background/Purpose: The transition from pediatric to adult healthcare is a vulnerable time for youth with chronic disease, with risks of disengagement from care and subsequent…
Abstract Number: 2431 • ACR Convergence 2024
DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
doria Andrea¹, Ronald Van Vollenhoven², Eric Morand³, Catharina Lindholm⁴, Jonatan Hedberg⁴, Miina Waratani⁵ and Danuta Kielar⁶, ¹University of Padova, Padova, Italy, ²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁵Biopharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁶Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: 2023 EULAR recommendations for the management of SLE open up the option for early treatment initiation with biologics without the requirement to fail immunosuppressants/DMARDs…
Abstract Number: 0620 • ACR Convergence 2024
Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial
Benjamin A. Fisher¹, Hendrika Bootsma², Vibeke Strand³, Wan-Fai Ng⁴, Thomas Wegman⁵, Brandon Becker⁶, Jiyoon Choi⁶, Antoine Sreih⁶, Leo Chen⁷, Antonia Christodoulou⁶ and Eric Morand⁸, ¹University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, ⁵Bristol Myers Squibb, Beaver Falls, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Richmond, BC, Canada, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
Abstract Number: 1466 • ACR Convergence 2024
Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks – Data from a Phase 4 Trial
Laure Gossec¹, Laura Coates², Dafna Gladman³, Alexis Ogdie⁴, Alvin F. Wells⁵, Joseph Merola⁶, Paolo Gisondi⁷, andreas pinter⁸, Mitsumasa Kishimoto⁹, Jyotsna Reddy¹⁰, Hamid Amouzadeh¹⁰, Rebecca Wang¹⁰, Shauna Jardon¹⁰, Michele Brunori¹⁰ and Philip Mease¹¹, ¹Sorbonne Université, Paris, France, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Rheumatology and Immunotherapy Center, Franklin, WI, ⁶UT Southwestern Medical Center, Newton, MA, ⁷Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, ⁸University Hospital of the Goethe University, Frankfurt am Main, Frankfurt, Germany, ⁹Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Most clinical trials of Psoriatic Arthritis (PsA) exclude patients with early oligoarticular (oligo) disease and there is limited evidence to drive treatment decisions in…
Abstract Number: 1678 • ACR Convergence 2024
Efficacy, Safety, Pharmacokinetics of Anti-CD40 Antibody Abiprubart in Patients with Rheumatoid Arthritis: A Phase 2, Randomized, Placebo-Controlled 12-week-treatment Proof-of-Concept Study
Eric Jenkins¹, Ingrid Louw², Attila Balog³, Elsa van Duuren⁴, diane Horowitz⁵, Janusz Jaworski⁶, Alan Kivitz⁷, Ilona Kemplerne Ujfalussy⁸, Joe Pirrello¹, Eben Tessari¹, Sheldon Wang¹ and John F Paolini¹, and KPL-404-C211 Investigators, ¹Kiniksa Pharmaceuticals, Lexington, MA, ²Panorama Medical Centre, Cape Town, South Africa, ³Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary, ⁴The Sefako Makgatho Health Science University, Pretoria, South Africa, ⁵Feinstein Institute for Medical Research, New York, NY, ⁶Reumatika-Centrum Reumatologii, Warszawa, Poland, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Medical Centre, Hungarian Defense Forces, Dózsa György út 112, Budapest, Hungary
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) with inadequate response or intolerance to current biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have limited options. Abiprubart, a humanized…
Abstract Number: 2269 • ACR Convergence 2024
Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial
Sadaf Atiqi¹, Maike Wientjes², Maureen Leeuw³, Laura Boekel⁴, Femke Hooijberg¹, Floris Loeff⁵, Charlotte Krieckaert¹, Annick De Vries⁵, Michael Nurmohamed⁶, Theo Rispens⁵, Maarten Boers⁷, Bart van den Bemt⁸, Alfons den Broeder² and Gertjan Wolbink⁹, ¹Reade, Amsterdam, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Reade, Zeist, Netherlands, ⁴Vrije Universiteit Amsterdam, Amsterdam, Netherlands, ⁵Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁶Reade and Amsterdam UMC, Kortenhoef, Netherlands, ⁷Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁸Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands, ⁹Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands
Background/Purpose: The latest European and American recommendations support tapering of biological DMARDs (bDMARDs) in patients with persistent remission or low disease activity. Most clinicians use…
Abstract Number: 2563 • ACR Convergence 2024
Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
Jean-Yves Reginster¹, Stuart L. Silverman², Edward Czerwinski³, Przemyslaw Borowy⁴, Tomasz Budlewski⁵, Joanna Kwiatek⁶, Svitlana Postol⁷, Airi Põder⁸, Jerzy Supronik⁹, SungHyun Kim¹⁰, JeeHye Suh¹⁰, GoEun Yang¹⁰, NooRi Han¹⁰, NaHyun Kim¹⁰ and SeoHee Bae¹⁰, ¹Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, ²OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, ³Krakow Medical Centre, Kraków, Poland, ⁴Krakowskie Centrum Medyczne, Krakow, Poland, ⁵Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁶Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, ⁷Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, ⁸Clinical Research Centre Ltd, Tartu, Estonia, ⁹Osteo-Medic s.c., Białystok, Poland, ¹⁰Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: CT-P41 is a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator of NF-κb ligand…
Abstract Number: 0662 • ACR Convergence 2024
Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
Eric Morand¹, Cristina Arriens², Laura Geraldino³, Ann E. Clarke⁴, Samantha Pomponi⁵, Coburn Hobar⁵, Thomas Wegman⁶, Ravi Koti⁵, Subhashis Banerjee⁵ and Ronald Van Vollenhoven⁷, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Department of Arthritis and Clinical Immunology, Rheumatology, Oklahoma Medical Research Foundation and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Beaver Falls, PA, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to severe…
Abstract Number: 1472 • ACR Convergence 2024
Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Natalie J. Shiff⁴, Anthony Todd⁵, Emmanouil Rampakakis⁶, Francois Nantel⁷, Jenna Parrett⁵, Frederic Lavie⁸ and Proton Rahman⁹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ³University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷Nantel Medsci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated multidomain efficacy (swollen/tender joints, psoriasis, enthesitis and dactylitis) in patients (pts) with active PsA in…
Abstract Number: 1680 • ACR Convergence 2024
Reporting Quality of Non-inferiority and Equivalence Rheumatoid Arthritis Randomized Clinical Trials: A Systematic Review
Osama Alalwan¹ and Majeed Haider², ¹Salmaniya Medical Complex, Bahrain, Bahrain, ²Salmaniya Medical Complex, Manama, Bahrain
Background/Purpose: The number of non-inferiority/equivalence randomized clinical trials (NI/EQ-RCTs) in the rheumatoid arthritis (RA) field has recently increased for various reasons. These designs require special…
Abstract Number: 2274 • ACR Convergence 2024
Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial
Asger Reinstrup Bihlet¹, Philip G Conaghan², Thomas Boesen³, Mette Arnum Jensen³, Alejandro Castillo Mondragón⁴, Ema Erkocevic Petersen⁴, Cathrine Borgsted Bak⁴ and Thomas EN Jonassen³, ¹NBCD A/S, Soeborg, Denmark, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Synact Pharma ApS, Holte, Denmark, ⁴NBCD A/S, Soborg, Denmark
Background/Purpose: AP1189 is a novel, first-in-class, oral, biased melanocortin (MC)1 and MC3 receptor agonist in development for Rheumatoid Arthritis (RA) treatment. Through multiple actions including…
Abstract Number: 2582 • ACR Convergence 2024
Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Iain McInnes¹, Laura Coates², Philip Mease³, Alexis Ogdie⁴, Arthur Kavanaugh⁵, Lihi Eder⁶, Georg Schett⁷, Alan Kivitz⁸, Nuala Brennan⁹, Alex Godwood⁹, Eva Cullen⁹, Kristian Reich⁹, Christopher Ritchlin¹⁰ and Joseph F. Merola¹¹, ¹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵University of California San Diego, La Jolla, CA, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁰Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sonelokimab is a novel humanized Nanobody designed to inhibit IL-17A and IL-17F and penetrate clinically relevant sites of inflammation. The 24-week Phase 2 ARGO…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.